Literature DB >> 27965110

Alterations in B-cell subsets in pediatric patients with early atopic dermatitis.

Tali Czarnowicki1, Hitokazu Esaki2, Juana Gonzalez3, Yael Renert-Yuval4, Patrick Brunner5, Margeaux Oliva4, Yeriel Estrada4, Hui Xu4, Xiuzhong Zheng5, Sreya Talasila6, Isabel Haugh6, Thy Huynh6, Sarah Lyon6, Gary Tran6, Hugh Sampson7, Mayte Suárez-Fariñas8, James G Krueger5, Emma Guttman-Yassky2, Amy S Paller6.   

Abstract

BACKGROUND: B cells undergo maturation and class-switching in response to antigen exposure and T-cell help. Early B-cell differentiation has not been defined in patients with early-onset atopic dermatitis (AD).
OBJECTIVE: We sought to define the frequency of B-cell subsets associated with progressive B-cell maturation and IgE class-switching.
METHODS: We studied 27 children and 34 adults with moderate-to-severe AD (mean SCORAD score, 55 and 65, respectively) and age-matched control subjects (15 children and 27 adults). IgD/CD27 and CD24/CD38 core gating systems and an 11-color flow cytometric panel were used to determine the frequencies of circulating B-cell subsets. Serum total and allergen-specific IgE (sIgE) levels were measured by using ImmunoCAP.
RESULTS: Compared with adults, children showed T-cell predominance in the skin. Circulating CD19+CD20+ B-cell counts were lower in patients with pediatric AD than in control subjects (24% vs 33%, P = .04), whereas CD3+ T-cell counts were higher (62% vs 52%, P = .05). A decreased B-cell/T-cell lymphocyte ratio with age was observed only in pediatric control subjects (r = -0.48, P = .07). In pediatric patients with AD, a positive correlation was observed between B-cell/T-cell ratio and nonswitched memory B-cell counts (r = 0.42, P = .03). Higher frequencies of positive sIgE levels were seen in pediatric patients with AD (P < .0001). Diverse sIgE levels correlated with SCORAD scores and age of pediatric patients with AD (P < .01). Positive correlations were observed between activated B-cell and memory T-cell counts (P < .02). In patients with AD, IgE sensitization to most allergens clustered with age, TH1, TH2, total IgE levels, and B-cell memory subsets.
CONCLUSIONS: Peripheral B and T cells are altered in pediatric patients with early AD, but T cells predominate in skin lesions.
Copyright © 2016 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Atopic dermatitis; B cells; T cells; allergen-specific IgE; atopic march

Mesh:

Substances:

Year:  2016        PMID: 27965110     DOI: 10.1016/j.jaci.2016.09.060

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  7 in total

Review 1.  The IL-13-OVOL1-FLG axis in atopic dermatitis.

Authors:  Kazuhisa Furue; Takamichi Ito; Gaku Tsuji; Dugarmaa Ulzii; Yen Hai Vu; Makiko Kido-Nakahara; Takeshi Nakahara; Masutaka Furue
Journal:  Immunology       Date:  2019-10-01       Impact factor: 7.397

Review 2.  Treatments for Childhood Atopic Dermatitis: an Update on Emerging Therapies.

Authors:  Chia-Yu Chu
Journal:  Clin Rev Allergy Immunol       Date:  2021-10       Impact factor: 8.667

Review 3.  Insights Into the Molecular Mechanisms of T Follicular Helper-Mediated Immunity and Pathology.

Authors:  Lei Qin; Tayab C Waseem; Anupama Sahoo; Shayahati Bieerkehazhi; Hong Zhou; Elena V Galkina; Roza Nurieva
Journal:  Front Immunol       Date:  2018-08-15       Impact factor: 7.561

4.  The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study.

Authors:  R Bissonnette; C Maari; S Forman; N Bhatia; M Lee; J Fowler; S Tyring; D Pariser; H Sofen; S Dhawan; M Zook; D J Zammit; H Usansky; L Denis; N Rao; T Song; A B Pavel; E Guttman-Yassky
Journal:  Br J Dermatol       Date:  2019-05-06       Impact factor: 9.302

5.  Comparison of the deep immune profiling of B cell subsets between healthy adults and Sjögren's syndrome.

Authors:  Ruiling Feng; Jing Zhao; Feng Sun; Miao Miao; Xiaolin Sun; Jing He; Zhanguo Li
Journal:  Ann Med       Date:  2022-12       Impact factor: 4.709

Review 6.  Tralokinumab for the Treatment of Atopic Dermatitis.

Authors:  Egídio Freitas; Emma Guttman-Yassky; Tiago Torres
Journal:  Am J Clin Dermatol       Date:  2021-06-21       Impact factor: 7.403

Review 7.  Tfh Cells in Health and Immunity: Potential Targets for Systems Biology Approaches to Vaccination.

Authors:  Hannah Law; Vanessa Venturi; Anthony Kelleher; C Mee Ling Munier
Journal:  Int J Mol Sci       Date:  2020-11-12       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.